Acta Neurologica Scandinavica

Cover image for Acta Neurologica Scandinavica

October 1991

Volume 84, Issue S136

Pages 5–98

  1. Preface

    1. Top of page
    2. Preface
    3. Original article
    1. Preface (page 5)

      Version of Record online: 29 JAN 2009 | DOI: 10.1111/j.1600-0404.1991.tb05012.x

  2. Original article

    1. Top of page
    2. Preface
    3. Original article
    1. Oxidative stress as a cause of Parkinson's disease (pages 6–15)

      P. Jenner and P. Jenner

      Version of Record online: 29 JAN 2009 | DOI: 10.1111/j.1600-0404.1991.tb05013.x

    2. Possible mechanisms underlying the special vulnerability of dopaminergic neurons (pages 16–18)

      A. Carlsson, B. Fornstedt and A. Carlsson

      Version of Record online: 29 JAN 2009 | DOI: 10.1111/j.1600-0404.1991.tb05014.x

    3. Metabolic biomarkers of Parkinson's disease (pages 19–23)

      A. Williams, S. Sturman, G. Steventon, R. Waring and A. Williams

      Version of Record online: 29 JAN 2009 | DOI: 10.1111/j.1600-0404.1991.tb05015.x

    4. Progression and survival in Parkinson's disease (pages 24–28)

      R. J. Marttila, U. K. Rinne and R. J. Marttila

      Version of Record online: 29 JAN 2009 | DOI: 10.1111/j.1600-0404.1991.tb05016.x

    5. What has PET told us about Parkinson's disease? (pages 37–39)

      S-M. Aquilonius

      Version of Record online: 29 JAN 2009 | DOI: 10.1111/j.1600-0404.1991.tb05018.x

    6. Optoelectronic movement analysis in Parkinson's disease: Effect of selegiline on the disability in de novo parkinsonian patients - a pilot study (pages 40–43)

      B. Johnels, P. E. Ingvarsson, M. Matousek, G. Steg and E. H. Heinonen

      Version of Record online: 29 JAN 2009 | DOI: 10.1111/j.1600-0404.1991.tb05019.x

    7. A review of the pharmacology of selegiline (pages 44–59)

      E. H. Heinonen and R. Lammintausta

      Version of Record online: 29 JAN 2009 | DOI: 10.1111/j.1600-0404.1991.tb05020.x

    8. Monoamine oxidase, dopamine and Parkinson's disease (pages 60–65)

      L. Oreland

      Version of Record online: 29 JAN 2009 | DOI: 10.1111/j.1600-0404.1991.tb05021.x

    9. Experience with selegiline and levodopa in advanced Parkinson's disease (pages 66–69)

      A. Lieberman and E. Fazzini

      Version of Record online: 29 JAN 2009 | DOI: 10.1111/j.1600-0404.1991.tb05022.x

    10. Selegiline as a primary treatment of Parkinson's disease (pages 70–72)

      V. V. Myllylä, K. A. Sotaniemi, J. A. Vuorinen and E. H. Heinonen

      Version of Record online: 29 JAN 2009 | DOI: 10.1111/j.1600-0404.1991.tb05023.x

    11. Selegiline in de novo parkinsonian patients: The French selegiline multicenter trial (FSMT) (pages 73–78)

      H. Allain, J. Cougnard and H-C. Neukirch

      Version of Record online: 29 JAN 2009 | DOI: 10.1111/j.1600-0404.1991.tb05024.x

    12. Selegiline hydrochloride and cognition (pages 91–94)

      A. J. Lees

      Version of Record online: 29 JAN 2009 | DOI: 10.1111/j.1600-0404.1991.tb05027.x

SEARCH

SEARCH BY CITATION